Merck & Company Inc (MRK)vsMaxCyte Inc (MXCT)
MRK
Merck & Company Inc
$120.60
+0.84%
HEALTHCARE · Cap: $283.78B
MXCT
MaxCyte Inc
$1.19
+2.50%
HEALTHCARE · Cap: $129.62M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 203598% more annual revenue ($65.77B vs $32.29M). MRK leads profitability with a 13.6% profit margin vs -121.2%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
MXCT
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$120.60
$39.64 premium
Intrinsic value data unavailable for MXCT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : MXCT
The strongest argument for MXCT centers on Price/Book, Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : MXCT
The primary concerns for MXCT are EPS Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
MRK profiles as a value stock while MXCT is a turnaround play — different risk/reward profiles.
MXCT carries more volatility with a beta of 1.67 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 28/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →MaxCyte Inc
HEALTHCARE · MEDICAL DEVICES · USA
MaxCyte Inc. (MXCT) is a leader in cell-engineering, renowned for its innovative Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins into a variety of cell types. The company serves a prestigious clientele, including top biopharmaceutical firms and research institutions, positioning it favorably within the rapidly expanding cell and gene therapy market. MaxCyte's advanced platforms play a crucial role in the development of novel cell-based therapies and vaccines, responding to the growing global demand for transformative healthcare solutions. With a steadfast commitment to enhancing patient outcomes, MaxCyte is poised to capitalize on significant market opportunities in the life sciences sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?